for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Homology Medicines Inc

FIXX.OQ

Latest Trade

13.33USD

Change

1.24(+10.26%)

Volume

149,079

Today's Range

11.92

 - 

13.51

52 Week Range

11.08

 - 

31.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.09
Open
12.09
Volume
149,079
3M AVG Volume
4.79
Today's High
13.51
Today's Low
11.92
52 Week High
31.80
52 Week Low
11.08
Shares Out (MIL)
43.97
Market Cap (MIL)
504.29
Forward P/E
-4.59
Dividend (Yield %)
--

Next Event

Q1 2020 Homology Medicines Inc Earnings Release

Latest Developments

More

Homology Medicines Reports Q3 Loss Per Share $0.67

Homology Medicines Q2 Loss Per Share $0.61

Homology Medicines Initiates Phase 1/2 Study For Hmi-102 Gene Therapy Candidate For Adults With Pku And Expects Initial Clinical Results By Year End 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Homology Medicines Inc

Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.

Industry

Retail (Drugs)

Contact Info

1 Patriots Park

+1.781.3017277

https://www.homologymedicines.com/

Executive Leadership

Arthur O. Tzianabos

President, Chief Executive Officer, Director

W. Bradford Smith

Chief Financial Officer, Treasurer and Secretary

Albert Seymour

Chief Scientific Officer

Tim Kelly

Chief Technical Operations Officer

Alise S. Reicin

Director

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-2.000

2019(E)

-2.434
Price To Earnings (TTM)
--
Price To Sales (TTM)
194.25
Price To Book (MRQ)
1.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-28.69
Return on Equity (TTM)
-27.45

Latest News

Latest News

BRIEF-Homology Medicines Reports Q1 Loss Per Share $0.64

* HOMOLOGY MEDICINES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up